Filing Details
- Accession Number:
- 0001209191-17-049702
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-08-21 17:15:09
- Reporting Period:
- 2017-08-17
- Accepted Time:
- 2017-08-21 16:15:09
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1373707 | Tetraphase Pharmaceuticals Inc | TTPH | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1598640 | Jacques Dumas | C/O Tetraphase Pharmaceuticals, Inc. 480 Arsenal Street Watertown MA 02472 | Chief Scientificofficer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2017-08-17 | 7,155 | $5.86 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- On January 6, 2016, the Reporting person was granted 35,000 restricted stock units ("RSUs")( the "2016 RSU grant") that were previously reported on Table II Of Form 4, which form was filed with the Securities and Exchange Commission on June 10, 2016. Of the 2016 RSU grant, 11,667 shares vested on January 6, 2017 of which 4,512 shares were withheld by the Issuer to satisfy the reporting person's tax withholding obligations in connection with the delivery of the conversion of the RSUs into common stock on the vesting date. The remaining 7,155 shares were sold on August 17, 2017 and such sale is reported on this Form 4.
- The sale of these shares of common stock reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 16, 2017.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $5.79 to $5.90 per share. The reporting person undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.